The novel extended-duration small interfering RNA lepodisiran reduced mean serum concentrations of lipoprotein(a) (Lp[a]) from 60 to 180 days after being administered subcutaneously, according to ...

The ALPACA trial showed that among patients with elevated lipoprotein(a), lepodisiran reduces mean serum concentrations of lipoprotein(a) from 60 to 180 days after administration. Participants were ...

Clopidogrel monotherapy was found to be more effective than aspirin monotherapy in lowering risk of major adverse cardiac and cerebrovascular events among patients at high risk of recurrent ischemic ...

The FRESH-UP study demonstrated that for patients with chronic heart failure (HF), liberal fluid intake did not result in a significant difference in health status vs. fluid restriction up to 1500 mL ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

An artificial intelligence (AI) model trained to detect blocked coronary arteries based on electrocardiogram (ECG) readings performed better than expert clinicians and was on par with troponin T ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with symptomatic peripheral artery disease (PAD) and Type 2 diabetes in the ...

Patients who have a stent implanted to open a blocked coronary artery face dual risks of developing blood clots and of having excessive bleeding in the months following the procedure. While routine ...

The HOST-BR trial demonstrated that for patients at either high or low risk of bleeding, 3 months is the optimal duration of treatment to reduce adverse events without increasing bleeding risk ...